Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB

Key Points

• Eversept Partners LP reduced its AnaptysBio stake by 77.6% in the first quarter, selling 93,838 shares and retaining 27,089 shares valued at approximately $1.5 million.
• AnaptysBio reported a quarterly loss of $1.84 per share, missing the $0.64 consensus estimate, although revenue of $25.56 million exceeded analyst expectations of $18.86 million.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus rating and an average price target of $82, compared with the stock’s reported price of $53.61.

Eversept Partners LP cut its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 77.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,089 shares of the biotechnology company's stock after selling 93,838 shares during the quarter. Eversept Partners LP owned about 0.09% of AnaptysBio worth $1,502,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ANAB. Los Angeles Capital Management LLC raised its stake in shares of AnaptysBio by 1.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company's stock valued at $732,000 after acquiring an additional 225 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 263 shares during the period. Larson Financial Group LLC grew its holdings in AnaptysBio by 21.2% during the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company's stock valued at $79,000 after purchasing an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC grew its holdings in AnaptysBio by 1.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company's stock valued at $1,743,000 after purchasing an additional 500 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 821 shares during the period.

AnaptysBio Price Performance

AnaptysBio stock opened at $53.61 on Tuesday. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -49.64 and a beta of 0.68. AnaptysBio, Inc. has a 1 year low of $11.40 and a 1 year high of $72.36. The firm has a 50-day moving average of $58.28 and a two-hundred day moving average of $57.64.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million for the quarter, compared to analyst estimates of $18.86 million. Research analysts expect that AnaptysBio, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ANAB. Leerink Partners set a $90.00 target price on AnaptysBio in a research report on Friday, May 15th. Barclays increased their price target on AnaptysBio from $63.00 to $75.00 and gave the stock an "overweight" rating in a report on Wednesday, May 13th. HC Wainwright initiated coverage on AnaptysBio in a research note on Wednesday, June 10th. They set a "buy" rating and a $95.00 price target for the company. Piper Sandler dropped their price objective on AnaptysBio from $95.00 to $93.00 and set an "overweight" rating for the company in a report on Monday, May 4th. Finally, UBS Group upped their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus price target of $82.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.